ReviewJournal of medicinal chemistry2002
Purine and pyrimidine (P2) receptors as drug targets.
Review in Journal of medicinal chemistry, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 107 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
107 citing papers in PubMed.
- Review
- Poly (I:C)-induced inflammation requires the activation of toll-like receptor 3/CaTheranostics · 2025Article
- Ionotropic purinergic receptor 7 (P2X7) channel structure and pharmacology provides insight regarding non-nucleotide agonism.Channels (Austin, Tex.) · 2024Review
- Pharmacology of P2X Receptors and Their Possible Therapeutic Potential in Obesity and Diabetes.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Structural insights into the orthosteric inhibition of P2X receptors by non-ATP analog antagonists.eLife · 2024Article
- Role and therapeutic targets of P2X7 receptors in neurodegenerative diseases.Frontiers in immunology · 2024Review
- Migraine signaling pathways: purine metabolites that regulate migraine and predispose migraineurs to headache.Molecular and cellular biochemistry · 2023Review
- The role of the ATP-adenosine axis in ischemic stroke.Seminars in immunopathology · 2023Review
- Antiproliferative Activity of (-)-Isopulegol-based 1,3-Oxazine, 1,3-Thiazine and 2,4-Diaminopyrimidine Derivatives.ChemistryOpen · 2022Article
- ATP, an attractive target for the treatment of refractory chronic cough.Purinergic signalling · 2022Review
- Role of the Purinergic P2Y2 Receptor in Pulmonary Hypertension.International journal of environmental research and public health · 2021Review
- Synthesis and biological evaluation ofRSC medicinal chemistry · 2021Article
- Adenosine kinase: A key regulator of purinergic physiology.Biochemical pharmacology · 2021Review
- Geoffery Burnstock's influence on the evolution of P2X3 receptor pharmacology.Purinergic signalling · 2021Review
- Frontline Science: P2Y11 receptors support T cell activation by directing mitochondrial trafficking to the immune synapse.Journal of leukocyte biology · 2021Article
- Novel cyanothiouracil and cyanothiocytosine derivatives as concentration-dependent selective inhibitors of U87MG glioblastomas: Adenosine receptor binding and potent PDE4 inhibition.European journal of medicinal chemistry · 2021Article
- P2X3 Receptor Ligands: Structural Features and Potential Therapeutic Applications.Frontiers in pharmacology · 2021Article
- P2X7R in Mast Cells is a Potential Target for Salicylic Acid and Aspirin in Treatment of Inflammatory Pain.Journal of inflammation research · 2021Article
- Role for ovarian hormones in purinoceptor-dependent natriuresis.Biology of sex differences · 2020Article
- Resolving the Ionotropic P2X4 Receptor Mystery Points Towards a New Therapeutic Target for Cardiovascular Diseases.International journal of molecular sciences · 2020Review
47 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.